First Time Loading...

Creo Medical Group PLC
LSE:CREO

Watchlist Manager
Creo Medical Group PLC Logo
Creo Medical Group PLC
LSE:CREO
Watchlist
Price: 36 GBX Market Closed
Updated: May 1, 2024
Section:
 

Wall Street
Price Targets

CREO Price Targets Summary
Creo Medical Group PLC

Wall Street analysts forecast CREO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CREO is 101.49 GBX with a low forecast of 99.99 GBX and a high forecast of 105 GBX.

CREO Lowest Forecast
Wall Street Target
99.99 GBX
178% Upside
CREO Average Forecast
Wall Street Target
101.49 GBX
182% Upside
CREO Highest Forecast
Wall Street Target
105 GBX
192% Upside
Lowest
Price Target
99.99 GBX
178% Upside
Average
Price Target
101.49 GBX
182% Upside
Highest
Price Target
105 GBX
192% Upside
Creo Medical Group PLC Competitors:
Price Targets
EKF
EKF Diagnostics Holdings PLC
11% Upside
M
041920
Mediana Co Ltd
224% Upside
AXGN
AxoGen Inc
117% Upside
MLSS
Milestone Scientific Inc
394% Upside
EKF
EKF Diagnostics Holdings PLC
11% Upside
M
041920
Mediana Co Ltd
224% Upside
AXGN
AxoGen Inc
117% Upside
MLSS
Milestone Scientific Inc
394% Upside
NPCE
Neuropace Inc
40% Upside
I
ITGR
Integer Holdings Corp
14% Upside
TNDM
Tandem Diabetes Care Inc
0% Downside
E
NVST
Envista Holdings Corp
23% Upside

Revenue
Forecast

Revenue Estimate
Creo Medical Group PLC

The compound annual growth rate of Creo Medical Group PLC's revenue for the next 4 years is 26%.

N/A
Past Growth
26%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Creo Medical Group PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
9%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Creo Medical Group PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-55%
Average Miss
What are analyst estimates?

See Also

Summary
CREO intrinsic value, competitors valuation, and company profile.
DCF Valuation
CREO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CREO stock valuation using valuation multiples.
Wall Street Estimates
CREO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CREO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CREO's stock price target?
Price Target
101.49 GBX

According to Wall Street analysts, the average 1-year price target for CREO is 101.49 GBX with a low forecast of 99.99 GBX and a high forecast of 105 GBX.

What is Creo Medical Group PLC's Revenue forecast?
Projected CAGR
26%

The compound annual growth rate of Creo Medical Group PLC's revenue for the next 4 years is 26%.

ALPHA SPREAD
Join more than 133,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.